Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy

New CML score applied to 1,414 patients with early-stage CML treated with IFN. m.s., median survival time. Confidence intervals for probability of survival are given at 3, 6, and 10 years for each group.

Patients with data on the New CML score and on hematologic response (n = 1,009). During the first (A) 6, (B) 9, and (C) 12 months after start of IFN therapy, survival probabilities of all patients were calculated together. For the (A) 997, (B) 966, and (C) 940 patients still under observation after 6, 9, and 12 months, respectively, 2 Kaplan-Meier curves were plotted from the landmark. The assignment of a patient to either curve depended on whether a CHR was recorded within the first 6, 9, or 12 months of IFN therapy, or not. Confidence intervals for probability of survival are given at 3, 6, and 10 years for each group. Log-rank test between “CHR” and “No CHR” for survival probabilities after 6, 9, and 12 months: P ≤ .0001 for all.

Patients with low risk at diagnosis according to the New CML score (n = 446) and with data on hematologic response. During the first 9 months after start of IFN therapy, survival probabilities of all patients were calculated together. For the 425 patients still under observation after 9 months, 2 Kaplan-Meier curves were plotted from this landmark. The assignment of a patient to either curve depended on whether a CHR was recorded within the first 9 months of IFN therapy or not. Confidence intervals for probability of survival are given at 3, 6, and 10 years for each group. Log-rank test between “CHR” and “No CHR” for survival probabilities after 9 months: P ≤ .0001.

Patients with intermediate risk at diagnosis according to the New CML score (n = 452) and with data on hematologic response. During the first 9 months after start of IFN therapy, survival probabilities of all patients were calculated together. For the 435 patients still under observation after 9 months, 2 Kaplan-Meier curves were plotted from this landmark. The assignment of a patient to either curve depended on whether a CHR was recorded within the first 9 months of IFN therapy, or not. Confidence intervals for probability of survival are given at 3, 6, and 10 years for each group. Log-rank test between “CHR” and “No CHR” for survival probabilities after 9 months: P ≤ .0001.

Patients with high risk at diagnosis according to the New CML score (n = 111) and with data on hematologic response. During the first 9 months after start of IFN therapy, survival probabilities of all patients were calculated together. For the 106 patients still under observation after 9 months, 2 Kaplan-Meier curves were plotted from this landmark. The assignment of a patient to either curve depended on whether a CHR was recorded within the first 9 months of IFN therapy, or not. Confidence intervals for probability of survival are given at 3, 6, and 10 years for each group. Log-rank test between “CHR” and “No CHR” for survival probabilities after 9 months: P = .0945.